Loading
A phase 1/2 trial of AZD4512 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT07123454 by AstraZeneca, with 91 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-03-01. Interventions recorded: AZD4512. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/